These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 26943772

  • 1. Dicer suppresses the malignant phenotype in VHL-deficient clear cell renal cell carcinoma by inhibiting HIF-2α.
    Fan Y, Li H, Ma X, Gao Y, Bao X, Du Q, Ma M, Liu K, Yao Y, Huang Q, Zhang Y, Zhang X.
    Oncotarget; 2016 Apr 05; 7(14):18280-94. PubMed ID: 26943772
    [Abstract] [Full Text] [Related]

  • 2. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function.
    Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH.
    Oncogene; 2000 Nov 16; 19(48):5435-43. PubMed ID: 11114720
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.
    Ma X, Fan Y, Gao Y, Zhang Y, Huang Q, Ai Q, Ni D, Chen W, Zhang P, Song E, Wang B, Shi T, Zheng T, Zhang X.
    Urol Oncol; 2014 Jan 16; 32(1):46.e9-17. PubMed ID: 24094887
    [Abstract] [Full Text] [Related]

  • 7. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation.
    Greene CJ, Sharma NJ, Fiorica PN, Forrester E, Smith GJ, Gross KW, Kauffman EC.
    Free Radic Biol Med; 2019 Mar 16; 133():295-309. PubMed ID: 30553971
    [Abstract] [Full Text] [Related]

  • 8. Tuberous sclerosis complex protein 1 expression is affected by VHL Gene alterations and HIF-1α production in sporadic clear-cell renal cell carcinoma.
    Damjanovic SS, Ilic BB, Beleslin Cokic BB, Antic JA, Bankovic JZ, Milicevic IT, Rodic GS, Ilic DS, Todorovic VN, Puskas N, Tulic CD.
    Exp Mol Pathol; 2016 Dec 16; 101(3):323-331. PubMed ID: 27845047
    [Abstract] [Full Text] [Related]

  • 9. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
    Kong HS, Lee S, Beebe K, Scroggins B, Gupta G, Lee MJ, Jung YJ, Trepel J, Neckers L.
    Mol Pharmacol; 2010 Dec 16; 78(6):1072-8. PubMed ID: 20813864
    [Abstract] [Full Text] [Related]

  • 10. The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.
    Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H.
    J Pathol; 2013 Mar 16; 229(4):525-34. PubMed ID: 23007793
    [Abstract] [Full Text] [Related]

  • 11. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
    Schödel J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR.
    Eur Urol; 2016 Apr 16; 69(4):646-657. PubMed ID: 26298207
    [Abstract] [Full Text] [Related]

  • 12. The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
    Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.
    Oncogene; 2012 Feb 09; 31(6):776-86. PubMed ID: 21725364
    [Abstract] [Full Text] [Related]

  • 13. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
    Petrella BL, Brinckerhoff CE.
    Cancer Biol Ther; 2009 Jul 09; 8(14):1389-401. PubMed ID: 19483472
    [Abstract] [Full Text] [Related]

  • 14. The up-regulation of NDRG1 by HIF counteracts the cancer-promoting effect of HIF in VHL-deficient clear cell renal cell carcinoma.
    Zhang ZY, Zhang SL, Chen HL, Mao YQ, Li ZM, Kong CY, Han B, Zhang J, Chen YH, Xue W, Zhai W, Wang LS.
    Cell Prolif; 2020 Jul 09; 53(7):e12853. PubMed ID: 32537867
    [Abstract] [Full Text] [Related]

  • 15. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH, Couvé S, Meurice G, Oréar C, Droin N, Chiquet M, Ferlicot S, Verkarre V, Vasiliu V, Molinié V, Méjean A, Dessen P, Giraud S, Bressac-De-Paillerets B, Gardie B, Tean Teh B, Richard S, Gad S.
    Int J Oncol; 2018 Oct 09; 53(4):1455-1468. PubMed ID: 30066860
    [Abstract] [Full Text] [Related]

  • 16. The relationship of erythropoietin overexpression with von Hippel-Lindau tumour suppressor gene mutations between hypoxia-inducible factor-1α and -2α in sporadic clear cell renal carcinoma.
    Gong K, Zhang N, Zhang K, Na Y.
    Int J Mol Med; 2010 Dec 09; 26(6):907-12. PubMed ID: 21042786
    [Abstract] [Full Text] [Related]

  • 17. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.
    Carroll VA, Ashcroft M.
    Cancer Res; 2006 Jun 15; 66(12):6264-70. PubMed ID: 16778202
    [Abstract] [Full Text] [Related]

  • 18. Expression of hypoxia-inducible factor 1alpha, hypoxia-inducible factor 2alpha, and von Hippel-Lindau protein in epithelial ovarian neoplasms and allelic loss of von Hippel-Lindau gene: nuclear expression of hypoxia-inducible factor 1alpha is an independent prognostic factor in ovarian carcinoma.
    Osada R, Horiuchi A, Kikuchi N, Yoshida J, Hayashi A, Ota M, Katsuyama Y, Melillo G, Konishi I.
    Hum Pathol; 2007 Sep 15; 38(9):1310-20. PubMed ID: 17555795
    [Abstract] [Full Text] [Related]

  • 19. A novel role of sphingosine kinase-1 in the invasion and angiogenesis of VHL mutant clear cell renal cell carcinoma.
    Salama MF, Carroll B, Adada M, Pulkoski-Gross M, Hannun YA, Obeid LM.
    FASEB J; 2015 Jul 15; 29(7):2803-13. PubMed ID: 25805832
    [Abstract] [Full Text] [Related]

  • 20. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
    Xu J, Wang B, Xu Y, Sun L, Tian W, Shukla D, Barod R, Grillari J, Grillari-Voglauer R, Maxwell PH, Esteban MA.
    Oncogene; 2012 Feb 23; 31(8):1065-72. PubMed ID: 21841824
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.